MeiraGTx Holdings plc (MGTX)
NASDAQ: MGTX · Real-Time Price · USD
6.16
-0.62 (-9.14%)
Apr 1, 2025, 4:00 PM EDT - Market closed

Company Description

MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases.

The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.

It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren’s syndrome; AAV-GAD in Phase 2 trial for Parkinson’s disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4.

In addition, the company’s products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer’s disease, and wet and dry neovascular age related macular degeneration.

Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain.

The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson’s disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system.

MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

MeiraGTx Holdings plc
MeiraGTx Holdings logo
Country United States
Founded 2015
Industry Biotechnology
Sector Healthcare
Employees 381
CEO Alexandria Forbes

Contact Details

Address:
450 East 29th Street, 14th Floor
New York, New York 10016
United States
Phone 646 860 7985
Website meiragtx.com

Stock Details

Ticker Symbol MGTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001735438
CUSIP Number G59665102
ISIN Number KYG596651029
Employer ID 98-1448305
SIC Code 2836

Key Executives

Name Position
Dr. Alexandria Forbes Ph.D. Chief Executive Officer, President and Director
Richard Brian Giroux B.A. Chief Operating Officer and Chief Financial Officer
Dr. Stuart Naylor Ph.D. Chief Development Officer
Robert J. Wollin J.D. General Counsel and Secretary
Dr. Michel Michaelides M.D. Head of Clinical Ophthalmology
Christine Elise Sheehy Senior Vice President of Global Integration
Tim Randall Senior Vice President of Risk and Internal Controls
Dr. Robert K. Zeldin M.D. Chief Medical Officer
Dr. David Rubinstein Ph.D. Senior Vice President of Business Development

Latest SEC Filings

Date Type Title
Mar 13, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 13, 2025 10-K Annual Report
Mar 13, 2025 8-K Current Report
Jan 21, 2025 144 Filing
Jan 7, 2025 144 Filing
Dec 9, 2024 8-K Current Report
Nov 13, 2024 10-Q Quarterly Report
Nov 13, 2024 8-K Current Report
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 18, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals